BioSpace News Archive

SQI Diagnostics Inc. (“SQI Diagnostics” or the “Company”) (TSX-V: SQD; OTCQB: SQIDF), today announced that it plans to release its financial and operational results for the fourth quarter and year ended September 30, 2019, at 5:30 p.m. ET Wednesday, December 11, 2019.

A behavioral geneticist who found that DNA is the primary force shaping our personalities has won the 2020 University of Louisville Grawemeyer Award for Psychology.

Economic activity in the non-manufacturing sector grew in November for the 118th consecutive month, say the nation’s purchasing and supply executives in the latest Non-Manufacturing ISM® Report On Business®.

$50 million global research initiative, funded by Leonard A. Lauder, Bill Gates, Jeff and MacKenzie Bezos, among other leading philanthropists, targets resources to speed up development of blood, digital and other biomarkers for early detection of Alzheimer’s disease and related dementias.

MediOrbis, a multi-specialty telemedicine and telehealth company with a first-of-its-kind chronic disease management (CDM) program, announces expanded access to its specialty physician network, comprehensive telemedicine services and the expansion of their co-branded, cutting-edge, digital and telehealth technology platform with MediGuide, a global concierge medical second opinion (MSO) company serving millions of members across 50+ countries globally

CB Therapeutics, Inc. has achieved the successful biosynthesis of psilocybin, psilocin and related tryptamine-based compounds typically found in plants and fungi and has filed a patent for the production process.

Testing Industry-Grade Wearable Devices for Real-Time Functional Assessment.

The ALS Association is partnering with, and will be directly investing in, the ALS Investment Fund II to raise $100 million to accelerate investment in ALS research and development.

IDTechEx, expert providers of emerging technology market intelligence and events, are bringing the conference on wearables and sensors in healthcare to San Jose, USA.

Gatehouse Bio, a pioneer in next-generation therapeutics, is collaborating with AstraZeneca, a global science-led biopharmaceutical company, to explore the identification of new targets for respiratory and cardiovascular diseases using Gatehouse Bio’s Artificial Intelligence (AI)-powered platform.